X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1885) 1885
life sciences & biomedicine (1697) 1697
humans (1556) 1556
sepsis (1469) 1469
male (1346) 1346
animals (1281) 1281
female (859) 859
mice (623) 623
sepsis - chemically induced (576) 576
sepsis - drug therapy (523) 523
inflammation (481) 481
middle aged (475) 475
adult (449) 449
lipopolysaccharides (414) 414
rats (391) 391
aged (380) 380
disease models, animal (366) 366
general & internal medicine (320) 320
abridged index medicus (319) 319
immunology (310) 310
cytokines (300) 300
lipopolysaccharides - toxicity (287) 287
sepsis - complications (283) 283
mice, inbred c57bl (264) 264
rodents (263) 263
mortality (243) 243
research article (239) 239
risk factors (219) 219
pharmacology & pharmacy (218) 218
cell biology (217) 217
sepsis - metabolism (217) 217
hematology (212) 212
health aspects (211) 211
critical care medicine (209) 209
medicine (208) 208
sepsis - etiology (208) 208
proteins (204) 204
research (202) 202
analysis (201) 201
inflammation - chemically induced (187) 187
science & technology - other topics (179) 179
time factors (175) 175
multidisciplinary sciences (174) 174
treatment outcome (174) 174
sepsis - pathology (172) 172
lipopolysaccharide (170) 170
rats, sprague-dawley (170) 170
physiology (168) 168
biochemistry & molecular biology (167) 167
infections (161) 161
science (161) 161
cardiovascular system & cardiology (159) 159
lipopolysaccharides - pharmacology (156) 156
surgery (156) 156
mitogens (154) 154
rats, wistar (152) 152
adolescent (150) 150
endotoxemia - chemically induced (148) 148
sepsis - immunology (146) 146
neutropenia - chemically induced (144) 144
septic shock (143) 143
sepsis - mortality (135) 135
acute kidney injury - chemically induced (134) 134
gene expression (132) 132
signal transduction (131) 131
sepsis - physiopathology (130) 130
oncology (129) 129
care and treatment (127) 127
antibiotics (126) 126
retrospective studies (124) 124
sepsis - blood (122) 122
peripheral vascular disease (118) 118
studies (118) 118
apoptosis (117) 117
tumor necrosis factor-alpha - metabolism (115) 115
patients (114) 114
infectious diseases (112) 112
mice, knockout (112) 112
physiological aspects (112) 112
anti-bacterial agents - adverse effects (111) 111
bacteria (111) 111
cells, cultured (111) 111
medicine, general & internal (111) 111
cell line (109) 109
medicine, research & experimental (109) 109
research & experimental medicine (109) 109
animal models (108) 108
inflammation - metabolism (108) 108
sepsis - microbiology (108) 108
microbiology (107) 107
pediatrics (107) 107
macrophages (106) 106
neutrophils (104) 104
child (102) 102
dose-response relationship, drug (101) 101
nitric oxide (101) 101
cytokines - metabolism (99) 99
medicine & public health (98) 98
mice, inbred balb c (98) 98
anti-bacterial agents - therapeutic use (97) 97
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2511) 2511
German (45) 45
French (40) 40
Japanese (16) 16
Russian (13) 13
Spanish (13) 13
Chinese (9) 9
Norwegian (8) 8
Polish (4) 4
Portuguese (4) 4
Swedish (3) 3
Dutch (2) 2
Hungarian (2) 2
Italian (2) 2
Bulgarian (1) 1
Danish (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 06/2017, Volume 18, Issue 6, pp. 770 - 778
Summary Background Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Sulfides - administration & dosage | Pancreatic Neoplasms - drug therapy | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Hyperglycemia - chemically induced | Leucovorin - adverse effects | Fluorouracil - adverse effects | Hypokalemia - chemically induced | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Hematologic Diseases - chemically induced | Sensation Disorders - chemically induced | Abdominal Pain - chemically induced | Pancreatic Neoplasms - pathology | Anemia - chemically induced | Thrombocytopenia - chemically induced | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Hypoalbuminemia - chemically induced | Maximum Tolerated Dose | Sepsis - chemically induced | Sulfides - adverse effects | Aged | Caprylates - administration & dosage | Caprylates - adverse effects | Organoplatinum Compounds - adverse effects | Lymphopenia - chemically induced | Enzymes | Medical colleges | Care and treatment | Metastasis | Antineoplastic agents | Cells | Antimitotic agents | Cancer patients | Chemotherapy | Pancreatic cancer | Physiological aspects | Product development | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 06/2017, Volume 18, Issue 6, pp. 792 - 802
Journal Article
The lancet oncology, ISSN 1470-2045, 06/2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis | Index Medicus
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
British journal of haematology, ISSN 1365-2141, 02/2019, Volume 185, Issue 2, pp. 297 - 310
Summary Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS)... 
atypical haemolytic uraemic syndrome | eculizumab | paroxysmal nocturnal haemoglobinuria | pharmacovigilance | safety | Life Sciences & Biomedicine | Hematology | Science & Technology | Humans | Middle Aged | Child, Preschool | Infant | Male | Fatigue - chemically induced | Meningococcal Infections - chemically induced | Fever - chemically induced | Opportunistic Infections - chemically induced | Young Adult | Adult | Female | Atypical Hemolytic Uremic Syndrome - drug therapy | Child | Infant, Newborn | Databases, Factual | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Pharmacovigilance | Pregnancy Complications - drug therapy | Pregnancy | Hemoglobins - deficiency | Adolescent | Complement Inactivating Agents - therapeutic use | Hemoglobinuria, Paroxysmal - drug therapy | Aged | Complement Inactivating Agents - adverse effects | Pregnancy Outcome | Virus diseases | Pneumonia | Pregnant women | Analysis | Bacterial pneumonia | Staphylococcal infections | Mortality | Septic shock | Urinary tract infections | Disease susceptibility | Receiving | Health risks | Risk reduction | Data processing | Infections | Pharmacology | Exposure | Urinary tract | Patients | Bacteremia | Mitigation | Risk assessment | Sepsis | Safety | Solid tumors | Health risk assessment | Viral infections | Tumors | Index Medicus | Red Cells and Iron | Research Paper
Journal Article
Journal Article